The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Abstract
HER2 mutations (HER2mut) induce endocrine resistance in estrogen receptor–positive (ER+) breast cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 18, 2022
- Source ID
- 10.1158/1078-0432.ccr-21-3418
Entities
People
- Alshad S. Lalani
- Brittney Haas
- Cynthia X. Ma
- Eric Winer
- Feng Gao
- Frances Valdez-albini
- Gretchen Kimmick
- Janice Lu
- Jason Jones
- Jill Anderson
- Jingqin Luo
- Julie R. Nangia
- Leslie Bucheit
- Lisa A Carey
- Mark D Pegram
- Matthew J Ellis
- Matthew P Goetz
- Melody Cobleigh
- Nancy U Lin
- Paul K Marcom
- Rachel A Freedman
- Richard Bryce
- Ron Bose
- Shana Thomas
- Timothy Pluard
Organizations
- Alvin J. Siteman Cancer Center
- Baylor College of Medicine
- Dana–Farber Cancer Institute
- Duke Cancer Institute
- Guardant Health Inc.
- Mayo Clinic
- Puma Biotechnology
- Rush University Medical Center
- Stanford University
- United States Department of Defense
- University of Miami
- University of North Carolina
- University of Southern California
- Washington University School of Medicine
- Washington University in St. Louis